ADC Therapeutics is the commercial-stage antibody-drug-conjugate company built on one product, ZYNLONTA, a CD19-directed ADC with accelerated approvals across the United States, Europe, China, and Canada for relapsed or refractory diffuse large B-cell lymphoma. Its first quarter told a familiar turnaround story on the surface: revenue up, losses narrowing, cash burn roughly cut in half, and a balance sheet just given a runway into 2028. Then the quarter's real event landed after the facts - and the market did not like it. There are two ways to read this stock. The first reads as quiet progress toward a de-risking of the franchise. The second - and the one the tape has enforced - reads the confirmatory-trial data as a headline win hiding a safety story that could limit exactly the expansion ZYNLONTA needs.
The financials were better, not worse. First-quarter 2026 revenue fell to $20.9 million from $23.0 million a year ago, but only because a one-time $5.0 million milestone in the prior-year quarter vanished; underlying product sales rose 15.1% to $20.0 million on higher volume and price. Net loss narrowed to $33.0 million from $38.6 million, and operating cash burn dropped to $29.7 million from $56.3 million - a direct payoff of a June 2025 restructuring that cut roughly 30% of the workforce and a June 2026 follow-on that cut another ~17%. Management said in late June that cash is sufficient into at least 2028.
What happened next is what matters. On June 3 the company reported topline results from LOTIS-5, the randomized confirmatory trial that must verify ZYNLONTA's clinical benefit to convert its accelerated approvals into full ones. The trial met its primary endpoint - progression-free survival with statistical significance - but with a safety profile the market found unacceptable, including a 13.2% rate of fatal treatment-emergent events in the ZYNLONTA arm versus 4.6% in the control, and an overall survival hazard ratio of 0.96 showing no survival benefit. The stock halved in a day, from the low-to-mid $3s to $1.32, and has not recovered; it trades at roughly $1.18 as of August 11, near its 52-week low of $0.78. The company still plans a pre-sBLA meeting with the FDA in August and an sBLA submission in the fourth quarter. The investment case is now a binary on whether the FDA, and then prescribers, forgive the safety data in exchange for the efficacy win. The financials improved; the stock collapsed. This report is about why both can be true.